| Vol. 13.40 – 13 October, 2022 |
| |
|
|
| By utilizing zebrafish optic cup formation, and combining novel transgenic lines and image analysis pipelines, investigators studied how ECM properties influenced cell migration in vivo. [Current Biology] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that bone morphogenetic protein 2 (BMP2) stimulation controls the spatial organization of BMP receptors (BMPRs) by segregating ALK3 from BMPRII into β3 integrin-containing focal adhesions. [Journal of Cell Biology] |
|
|
|
| The adhesion, proliferation, morphology, and adhesion strength of NIH/3T3 cells on acetylated-polyrotaxanes (PRXs)-coated surfaces were found to be similar to those of the uncoated and unmodified PRX-coated surfaces. [Biomacromolecules] |
|
|
|
| Human-derived bone marrow stem cells showed an enhanced release profile of growth factors and exosomes in the fast stress relaxing gellan gum hydrogel. [International Journal of Biological Macromolecules] |
|
|
|
| Myosin 5b (MYO5B) is a molecular motor that traffics ion transporters to the apical membrane of enterocytes, and researchers tested to see if MYO5B may also be responsible for the localization of intermicrovillar adhesion complex proteins. [American Journal of Physiology-Gastrointestinal and Liver Physiology] |
|
|
|
| Stem cell spheroid was encapsulated by interfacial assembly of metal-phenolic network nanofilm to form a stem cell microsphere capsule. [International Journal of Oral Science] |
|
|
|
| Beta cyclodextrin-modified alginate/cartilage ECM-based interpenetrating polymer network hydrogel was developed for sustained release of Kartogenin. [Journal of Biomaterials Applications] |
|
|
|
|
| The authors provide a comprehensive summary of functional modes, design principles, and current and future applications for hydrogel interfaces toward merging humans and machines. [Nature Reviews Materials] |
|
|
|
|
| NextCure, Inc. announced the initiation of a Phase Ib/II clinical trial to evaluate NC410 in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors. [NextCure, Inc.] |
|
|
|
|
| November 7 – 9, 2022 Singapore, Singapore |
|
|
|
|
|
| Luxembourg Institute of Health – Luxembourg, Luxembourg |
|
|
|
| Eindhoven University of Technology – Eindhoven, Netherlands |
|
|
|
| Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Garvan Institute of Medical Research – Sydney, Australia |
|
|
|
|